Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Sanofi (SNY, SNYNF)

CIK 0001121404
$534.0M
Reported AUM
10
Positions
Q2 2026
Period
2026-07-28
Filed

Editorial summary

Summary for Sanofi (SNY, SNYNF) · Q2 2026 is not yet generated. It will appear here after the next nightly run.

Portfolio · Q2 2026

MGTX$164.8MINBX$109.7MNVAX$64.8MANAB$55.5MODTX$37.3MAGMB$36.1MMPLT$32.7MTRAXIMRXSS

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1MGTXMeiraGTx Holdings plc$11.983.10%56.60%-4.24%$164.8M30.86%HELD
2INBXInhibrx Biosciences, Inc.$84.736.91%292.27%497.95%$109.7M20.54%HELD
3NVAXNovavax$7.441.36%13.41%-96.88%$64.8M12.14%HELD
4ANABAnaptysBio$55.045.56%224.54%212.89%$55.5M10.39%HELD
5ODTXOdyssey Therapeutics Inc.$18.422.05%12.18%-1.55%$37.3M6.98%HELD
6AGMBAgomab Therapeutics NV$12.762.90%-12.94%21.59%$36.1M6.76%HELD
7MPLTMapLight Therapeutics Inc.$14.03-6.59%-14.57%6.05%$32.7M6.12%HELD
8TRAXFirst Tracks Biotherapeutics Inc.$47.7814.12%103.32%199.37%$16.5M3.10%HELD
9IMRXImmuneering Corp$4.234.32%25.52%-82.71%$13.5M2.53%HELD
10QTTBQ32 Bio Inc.$15.566.28%635.25%-88.64%$3.1M0.58%HELD

Source: SEC EDGAR · accession 0001193125-26-318812. 13F discloses long positions only — shorts, foreign equities, and options are excluded.